feedback

Course Director

Kimberly Halla, MSN, FNP-C
Kimberly Halla, MSN, FNP-C

Arizona Oncology Associates PC
Scottsdale, Arizona

Accredited by

Medical Learning Institute, Inc.

Activity Description

In this CNE activity, a family nurse practitioner brings the nurse’s perspective to patient care in endometrial and cervical cancer. Kimberly Halla, MSN, FNP-C, discusses modern management techniques for patient’s receiving targeted therapy and immunotherapy, as well as combination therapies, and gives her take on how to approach the unique safety profiles associated with these treatment options.

Target Audience

This activity has been designed to meet the educational needs of oncology nurses and other clinicians involved in the management of patients with cervical and endometrial cancers.

Educational Objectives

Upon completion of this activity, participants will be able to:
  • Summarize the current treatment and regulatory landscape in the management of gynecologic cancers, including the role of novel targeted, immunotherapeutic, and combination approaches in cervical and endometrial cancers
  • Describe safety and efficacy evidence surrounding targeted, immune checkpoint inhibitor, and combination strategies for the management of gynecologic cancers
  • Educate patients about therapeutic and safety considerations associated with recently approved and emerging options for endometrial and cervical cancers
  • Manage the unique spectrum of adverse events associated with targeted and immunotherapy used to treat endometrial and cervical cancers

Providership, Credit, and Support


This CNE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported by educational grants from GlaxoSmithKline, Merck & Co., Inc., and Seattle Genetics.

Continuing Nursing Education

ANCC Medical Learning Institute, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Successful completion of this continuing nursing education activity will be awarded 1.0 contact hour.

Faculty Disclosures

Chair
Kimberly Halla, MSN, FNP-C
Family Nurse Practitioner
Arizona Oncology Associates PC
Scottsdale, Arizona

Kimberly Halla, MSN, FNP-C, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with GlaxoSmithKline and Merck & Co., Inc.

Planning Committee Disclosures

Tracy L. Greene, MSN, RN, FNP-C, Lead Nurse Planner, MLI, has nothing to disclose.

The planners from Medical Learning Institute, Inc., the accredited provider, and PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewer has nothing to disclose:

Pamela Ash, RN, MSN, CBCN

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CNE credit. There are no prerequisites and there is no fee to participate in this activity or to receive CNE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

About This CNE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Activity Description

In this activity, oncology nurse experts discuss evidence on the safety and efficacy of novel therapeutics for the treatment of acute myeloid leukemia (AML) and, using a series of case scenarios, provide guidance on how to integrate innovative treatment options into the care of different AML populations.

Target Audience

This activity has been designed to meet the educational needs of oncology nurses and other clinicians involved in the care of patients with AML.

Educational Objectives

Upon completion of this activity, participants will be able to:
  • Cite updated evidence about the efficacy and safety of newer cytotoxic, targeted, and epigenetic strategies for the management of AML
  • Manage safety considerations in patients with AML who are receiving novel cytotoxic or targeted therapeutics
  • Address psychosocial, longer-term care, dosing, and adherence considerations in patients with AML who are receiving novel therapeutics
  • Educate patients about the clinical benefits of novel therapies, relevant prognostic factors, and potential safety issues associated with newly approved treatments for AML

Providership, Credit, and Support


This CNE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported through independent educational grants from AbbVie, Bristol Myers Squibb, and Jazz Pharmaceuticals, Inc.

Continuing Nursing Education

ANCCMedical Learning Institute, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Successful completion of this continuing nursing education activity will be awarded 1.0 contact hour(s).

Faculty Disclosures

Chair
Sara M. Tinsley, PhD, APRN, AOCN
Nurse Practitioner, Malignant Hematology
Moffitt Cancer Center
Courtesy Instructor
University of South Florida, College of Nursing
Tampa, Florida

Sara M. Tinsley, PhD, APRN, AOCN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Celgene Corporation and Incyte.
Speakers Bureau participant with Astellas Pharma US, Inc.; Bristol Myers Squibb; Celgene Corporation; Incyte; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical Company Limited.

Faculty
Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Hematology/Oncology Nurse Practitioner
Associate Clinical Professor
University of California San Francisco
San Francisco, California

Laura J. Zitella, MS, RN, ACNP-BC, AOCN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Merck & Co., Inc.

Planning Committee Disclosures

Tracy L. Greene, MSN, RN, FNP-C, Nurse Planner, MLI, has nothing to disclose.

The planners from Medical Learning Institute, Inc., the accredited provider, and PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewer has nothing to disclose:

Janice Trainor-Tellier, MSN, RN

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CNE credit. There are no prerequisites and there is no fee to participate in this activity or to receive CNE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

About This CNE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.